Venkata M Yenugonda

US Patent:

20120149663, Jun 14, 2012

Filed:

Aug 18, 2010

Appl. No.:

13/390731

Inventors:

Milton L. Brown - Brookeville MD, US
Venkata M. Yenugonda - McLean VA, US
Yali Kong - Centerville VA, US

Assignee:

GEORGETOWN UNIVERSITY - Washington DC

International Classification:

A61K 31/69
A61P 35/00
C07F 5/02

US Classification:

514 64, 548110, 564 8, 568 3, 568 6

Abstract:

Disclosed are compounds and methods related to boronic acid derivatives of resveratrol. Certain of these derivatives have enhanced efficacy relative to resveratrol, function as irreversible modulators, and act at the GI/S phase of the cell cycle.

US Patent:

20110269178, Nov 3, 2011

Filed:

Aug 17, 2009

Appl. No.:

13/059180

Inventors:

Venkata Mahidhar Yenugonda - McLean VA, US
Milton L. Brown - Brookeville MD, US

Assignee:

Georgetown University - Washington DC

International Classification:

C12Q 1/04
C12N 5/00
C07D 473/16

US Classification:

435 34, 544277, 435366

Abstract:

Disclosed are molecules and their synthesis. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.

US Patent:

20170107197, Apr 20, 2017

Filed:

May 23, 2016

Appl. No.:

15/162237

Inventors:

- Washington DC, US
- Durham NC, US
Yingxian Xiao - Potomac MD, US
Kenneth J. Kellar - Bethesda MD, US
Venkata M. Yenugonda - McLean VA, US
Edward D. Levin - Chapel Hill NC, US
Amir H. Rezvani - Chapel Hill NC, US

International Classification:

C07D 401/12
C07D 213/65

Abstract:

Disclosed are compounds and methods of using them to treat a disorder selected from the group consisting of addiction, pain, obesity, schizophrenia, epilepsy, mania and manic depression, anxiety, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder (ADHD), Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, inflammation, stroke, spinal cord injury, dyskinesias, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, autism, mutism, trichotillomania, hypothermia, and disorders of sleep.

US Patent:

20140323461, Oct 30, 2014

Filed:

Nov 9, 2012

Appl. No.:

14/357701

Inventors:

- Washington DC, US
Mikell A. Paige - Fairfax VA, US
Yingxian Xiao - Potomac MA, US
Kenneth J. Kellar - Bethesda MD, US
Venkata M. Yenugonda - McLean VA, US
Edward D. Levin - Chapel Hill NC, US
Amir H. Rezvani - Chapel Hill NC, US

International Classification:

C07D 401/12
C07D 213/65

US Classification:

5142102, 5462681, 546300

Abstract:

Disclosed are compounds and methods of using them to treat a disorder selected from the group consisting of addiction, pain, obesity, schizophrenia, epilepsy, mania and manic depression, anxiety, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder (ADHD), Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, inflammation, stroke, spinal cord injury, dyskinesias, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, autism, mutism, trichotillomania, hypothermia, and disorders of sleep.